ArticleNature communications2026
Retinocortical in-sensor neuromorphic vision platform for NIR-augmented artificial vision.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
In-sensor neuromorphic vision platforms with near-infrared (NIR) sensitivity are essential for intelligent imaging in low-light and multispectral environments. Here, a retinocortical dual-mode platform based on evolved-synaptic transistor (Evo-SynT) devices using upconversion nanoparticles (UCNP) and their integration into evolved-retina optical synapse (EROS) arrays is introduced. Evo-SynT devices exhibit key synaptic features, including paired-pulse facilitation indices exceeding 183.93% and 136.36% at a 0.5 s interval under 808 nm and 940 nm illumination, respectively, and analog weight modulation across 512 conductance states. A 12×12 EROS array enables dual-mode operation: retinal-like in-sensor preprocessing and cortical-like in-memory classification. The EROS array improves pedestrian detection accuracy under low-light conditions from 0.7806 to 0.8481 (808 nm) and 0.9071 (940 nm), and achieves classification accuracies of 77.19% and 79.40%, respectively. These results highlight the EROS platform as a scalable solution for integrated NIR-sensitive neuromorphic vision systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.